CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma

The purpose of this study is to determine the efficacy and safety of CD19/CD22 Chimeric Antigen Receptor (CAR) T-Cell immunotherapy as first-line consolidation therapy in patients with follicular lymphoma.

Trial Details

NCT ID
NCT07587840
Phase
PHASE2
Sponsor
Liping Dou
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • CD22/CD19 CAR-T cell immunotherapy
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • 1\. With the patient's consent and signed informed consent form, willing and able to comply with the planned visits, research treatments, laborator…
  • 2\. CD19 and/or CD22-positive follicular lymphoma (FL) confirmed by histology according to the WHO classification:
  • The patient's disease is still evaluated as partial response (PR) after induction treatment with standard first-line chemotherapy regimen, or
  • The patient's disease reaches complete response (CR) after induction treatment with standard first-line chemotherapy regimen, but there are high-ri…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →